Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
Apremilast
Patient Benefit Index
Patient-reported outcomes
Psoriasis
Real-world study
Treatment satisfaction
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
29
07
2021
accepted:
04
10
2021
pubmed:
24
11
2021
medline:
24
11
2021
entrez:
23
11
2021
Statut:
ppublish
Résumé
In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast. We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics. APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0-100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations. Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores. Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes.
Identifiants
pubmed: 34813044
doi: 10.1007/s13555-021-00628-3
pii: 10.1007/s13555-021-00628-3
pmc: PMC8776914
doi:
Types de publication
Journal Article
Langues
eng
Pagination
81-95Informations de copyright
© 2021. The Author(s).
Références
Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–50.
doi: 10.1016/j.cyto.2014.12.014
Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-23 (discussion ii24-15).
pubmed: 15708928
pmcid: 1766861
Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81.
doi: 10.1016/j.jaad.2013.12.018
Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92(3):299–303.
doi: 10.2340/00015555-1273
Kocic H, Damiani G, Stamenkovic B, et al. Dietary compounds as potential modulators of microRNA expression in psoriasis. Ther Adv Chronic Dis. 2019. https://doi.org/10.1177/2040622319864805 .
doi: 10.1177/2040622319864805
pubmed: 31431821
pmcid: 6686315
Carvalho AL, Hedrich CM. The molecular pathophysiology of psoriatic arthritis—the complex interplay between genetic predisposition, epigenetics factors, and the microbiome. Front Mol Biosci. 2021;8:662047.
doi: 10.3389/fmolb.2021.662047
Damiani G, Cazzaniga S, Conic RR, Naldi L. Pruritus characteristics in a large Italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316–24.
doi: 10.1111/jdv.15539
Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol. 2015;29(6):1114–20.
doi: 10.1111/jdv.12761
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
doi: 10.1016/j.jaut.2015.07.008
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–51.
doi: 10.2340/00015555-0770
Kleyn CE, Talbot PS, Mehta NN, et al. Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk. Acta Derm Venereol. 2020;100(1):adv00020.
doi: 10.2340/00015555-3375
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–5.
doi: 10.1001/jamadermatol.2013.5264
Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61–8.
pubmed: 25114561
pmcid: 4089835
Mueller SM, Itin PH, Navarini AA, et al. The relationship between PASI and DLQI with itch, stress, and depression: do we need additional decision-making tools in psoriasis? Dermatol Ther. 2020;33(3):e13276.
pubmed: 32060994
Schaarschmidt ML, Kromer C, Herr R, et al. Patient preferences for biologicals in psoriasis: top priority of safety for cardiovascular patients. PLoS One. 2015;10(12):e0144335.
doi: 10.1371/journal.pone.0144335
Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285–94.
doi: 10.1001/archdermatol.2011.309
Sumpton D, Kelly A, Tunnicliffe DJ, et al. Patients’ perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res (Hoboken). 2020;72(5):711–22.
doi: 10.1002/acr.23896
Schafer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010;20(1):62–7.
doi: 10.1684/ejd.2010.0815
Black N, Varaganum M, Hutchings A. Relationship between patient reported experience (PREMs) and patient reported outcomes (PROMs) in elective surgery. BMJ Qual Saf. 2014;23(7):534–42.
doi: 10.1136/bmjqs-2013-002707
Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319.
doi: 10.1007/s00403-018-1808-x
Augustin M, Kleyn CE, Conrad C, et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35(1):123–34.
doi: 10.1111/jdv.16431
Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301(8):561–71.
doi: 10.1007/s00403-009-0928-8
Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304(6):433–41.
doi: 10.1007/s00403-012-1256-y
Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
doi: 10.1186/1477-7525-7-36
Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol. 2014;70(2):390–1.
doi: 10.1016/j.jaad.2013.09.030
Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9(2):131–5.
doi: 10.1111/j.1087-0024.2004.09115.x
Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78.
doi: 10.1007/s00403-015-1613-8
Maul JT, Navarini AA, Sommer R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis—a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–8.
doi: 10.1111/jdv.15324